U.S. market Closed. Opens in 7 hours 38 minutes

DARE | Daré Bioscience, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for DARE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak.

Valuation (10%)

Company Industry
P/E Ratio (TTM) -4.57 -22.37
PEG Ratio (TTM) -0.06 15.65
P/S Ratio (TTM) 11.77 49.21
P/B Ratio (TTM) 12.31 18.45
P/FCF Ratio (TTM) -1.11 -1.64
Price to 5YR AVG Earnings Ratio -0.51 -2.80
Price to 5YR AVG FCF Ratio -1.34 -8.54

Profitability (50%)

Company Industry
ROA (TTM) -30.51% -4.65%
ROE (TTM) 183.89% 20.33%
Net Profit Margin (TTM) -253.60% -1,544.80%
ROIC 5YR AVG 262.33% 16.10%

Growth (25%)

4QTR AVG 3YR AVG 5YR AVG
EPS 79.71% -102.04% -51.80%
Revenue 30.63% N/A -14.38%
Net Income 75.47% -28.29% -12.61%
Cash Flow -1.76% -44.39% -42.18%

Health (14%)

Company Industry
Current Ratio (TTM) 1.43 6.09
Quick Ratio (TTM) 1.43 5.81
D/E Ratio (TTM) 1.80 -16.41
Interest Coverage (TTM) -3,501.06 -0.80
Piotroski F-Score N/A 5
Altman Z-Score N/A 13.80
LTL to 5YR AVG FCF -0.16 0.17
Shares Outstanding Growth 5YR AVG 30.00% 128.83%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙